Findings
========

Introduction
------------

Prevention and control of MRSA cross infection is among the most important challenges of infection control. Surveillance of all patients for MRSA carriage on admission to hospital allows those patients colonised with MRSA to be isolated and contact precautions undertaken, with the aim of minimising spread to other patients. As patients with MRSA evident on routine clinical specimens represents a small fraction of the burden of MRSA, surveillance is needed to identify the reservoir of colonised but not infected patients \[[@B1],[@B2]\]. However, universal surveillance utilises significant healthcare resources, and its effectiveness is debatable \[[@B3]-[@B5]\]. Despite this, screening is increasingly utilised in hospital MRSA control programs, and is still legislated in the United Kingdom and some states of the USA \[[@B6],[@B7]\]. To mitigate costs without sacrificing the effectiveness of surveillance, many MRSA screening programs rely on clinical prediction tools to target patients at high risk of MRSA carriage \[[@B5]\]. Several epidemiological studies form the basis of these tools in which the major risk factors for MRSA carriage have been identified, including: a history of MRSA colonization, admission to intensive care, hospitalization in the previous 12 months, extensive contact with health care, previous receipt of antibiotic therapy and skin or soft tissue infection at admission \[[@B8]-[@B12]\]. However, these studies report 5-83% of patients who were eligible for study, but not screened. The characteristics of these missed patients are seldom described \[[@B11]\]. We examined the characteristics of patients who were missed during a MRSA surveillance study at our institution to ascertain whether their exclusion might introduce bias and affect the accuracy of clinical prediction tools and risk profiling. Specifically, we hypothesised that an important proportion of patients would be missed by our MRSA screening programme, and that these patients would differ from those patients who were not missed.

Setting and methods
-------------------

The University of Geneva Hospitals (HUG) are a 2200-bed tertiary hospital network providing in- and outpatient care to the Canton of Geneva. From March to June 2010 a universal MRSA surveillance program was undertaken to prospectively screen all patients consecutively admitted to 13 internal medicine wards. The primary aim of this study was to determine the rate of MRSA carriage amongst patients admitted to internal medicine. Secondary aims included: to formulate a clinical prediction tool that would accurately predict those patients at high risk of MRSA carriage on admission to internal medicine, and to: determine the effectiveness of our programme to capture all patients for screening. Over the study period, all patient admissions to internal medicine were recorded and basic demographic and clinical data was collected. Further clinical data were obtained by retrospectively accessing electronic medical records. All patients \>18 years of age were eligible for screening and were screened for MRSA by pooled nose and groin swabs. Trained ward nurses conducted the screening seven days a week. Pooled samples were streaked onto MRSAid agar (bioMérieux, Lyon, France) and then inoculated into a colistin-salt (CS) broth. When no MRSA was detected on chromogenic agar at day 1, a second MRSAid plate was inoculated using the overnight enrichment in the CS broth. Suspect colonies were confirmed by a duplex polymerase chain reaction to assess the presence of the *mecA* gene \[[@B13]\].

The proportion of patients who were eligible for, but did not have MRSA screening was determined. Wilcoxon rank sum tests and chi^2^-tests were used to assess differences between screened and unscreened groups. Factors potentially associated with failure to screen were first evaluated using univariate logistic regression. Variables with a *P* value \<0.2 were retained. Multivariate models were then developed and variables were eliminated in a stepwise fashion using likelihood ratio tests to compare each model to the previous one (STATA 11.2; StataCorp, College Station, Texas, USA).

Results
=======

Of 1968 patients admitted to internal medicine, 1740 (88.4%) underwent admission screening within 48 hours of admission. 228 (11.6%) admitted patients were not screened and 39 (2.0%) patients underwent screening but not within 48 hours of admission. Therefore, 267 patients (13.6%) failed to undergo appropriate MRSA screening. Forty-one (2.4%) screened patients were MRSA carriers at admission. Patients who were missed during MRSA screening were younger (57.1 years vs 61.6 years; *P* \< 0.0001) and a greater percentage had been transferred to internal medicine from another hospital ward (7.0% vs 2.7%; *P* \< 0.0001). The proportions of patients identified as previous MRSA carriers was not significantly different between the screened and unscreened groups (9.6% vs 13.2%, respectively, *P* = 0.308). There was no significant difference in the proportion of patients missed by screening on weekends as compared to weekdays. The results of uni- and multivariate regression analysis of factors potentially associated with being missed for MRSA screening are shown in the Table [1](#T1){ref-type="table"}. On multivariate regression, patients who were missed by screening were more likely to be aged \< 50 years, admitted to internal medicine from another hospital, and have a history of malignancy.

###### 

Results of uni- and multi-variate regression analyses of factors associated with failure to have an admission MRSA swab performed^1^

                                           **Proportions (n)**   **Univariate regression**  **Multivariate regression**                               
  --------------------------------------- --------------------- --------------------------- ----------------------------- --------- ----------------- ---------
  Male sex                                     55.9 (148)               58.6 (997)          0.9 \[0.7-1.1\]               0.402                        
  Age \< 50 years old                           30.3 (81)               19.9 (339)          1.7 \[1.3-2.3\]               \<0.001   2.4 \[1.4-3.9\]   \<0.001
  Admitted from ICU                              4.5(12)                 7.6(129)           0.6 \[0.3-1.1\]               0.074                        
  Admitted from another ward                     7.1(19)                  2.7(45)           2.8 \[1.6-4.9\]               \<0.001   2.8 \[1.1-7.1\]   0.028
  Admitted from home                            88.3(235)               89.7(1526)          0.9 \[0.6-1.3\]               0.484                        
  Uncomplicated diabetes mellitus                10.4(12                 18.7(126)          0.5 \[0.3-0.9\]               0.034                        
  Acute renal failure                            10.4(12                 21.8(147)          0.4 \[0.2-0.8\]               0.006                        
  Chronic renal failure                          6.1(7)                  13.8(93)           0.4 \[0.2-0.9\]               0.026                        
  End stage renal failure                        4.3(5)                   2.4(16)           1.9 \[0.7-5.2\]               0.231                        
  Complicated diabetes mellitus                  5.2(6)                   9.8(66)           0.5 \[0.2-1.2\]               0.122                        
  Peripheral vascular disease                    2.6(3)                   4.3(29)           0.6 \[0.2-2.0\]               0.400                        
  Chronic obstructive pulmonary disease          9.6(11)                 14.4(97)           0.6 \[0.3-1.2\]               0.167                        
  Dementia                                       0.9(1)                   1.5(10)           0.6 \[0.07-4.6\]              0.608                        
  Stroke                                            0                     0.9(6)            Omitted                                                    
  Cerebral haemorrhage                           1.0(1)                   0.4(3)            2.0 \[0.2-19.0\]              0.561                        
  Congestive cardiac failure                    11.3(13)                 24.8(167)          0.4 \[0.2-0.7\]               0.002                        
  Ischaemic heart disease                       10.4(12)                 11.3(76)           0.9 \[0.5-1.8\]               0.791                        
  Haematological malignancy                     10.4(12)                  5.8(39)           1.9 \[1.0-3.7\]               0.065                        
  Carotid artery stenosis                           0                     1.2(8)            Omitted                                                    
  Parkinsons disease                             0.9(1)                   0.7(5)            1.2 \[0.1-10.2\]              0.884                        
  Connective tissue disease                      0.9(1)                   2.2(15)           0.4 \[0.05-2.9\]              0.358                        
  Liver failure                                  1.0(1)                   1.8(12)           0.5 \[0.06-3.8\]              0.488                        
  Respiratory failure                               0                     1.0(7)            Omitted                                                    
  Solid organ cancer                            35.7(41)                 15.4(104)          3.0 \[1.9-4.7\]               \<0.001   3.2\[2.1-5.1\]    \<0.001
  Metastatic cancer                             12.6(13)                  7.3(50)           1.8 \[0.3-3.9\]               0.866     2.6 \[1.4-4.8\]   0.004
  Peptic ulcer disease                           1.9(2)                   2.5(17)           1.1 \[0.3-3.9\]               0.866                        
  Infection                                      1.9(2)                   0.7(5)            2.4 \[0.5-12.5\]              0.301                        
  Day of the week                                                                                                                                      
  Monday                                        8.90(35)                91.10(358)          0.8\[0.4-1.4\]                0.355                        
  Tuesday                                       16.02(62)               83.98(325)          1.5\[0.9-2.5\]                0.140                        
  Wednesday                                     15.93(54)               84.07(285)          1.5\[0.9-2.5\]                0.155                        
  Thursday                                      16.08(46)               83.92(240)          1.5\[0.9-2.6\]                0.153                        
  Friday                                        15.49(35)               84.51(191)          1.4\[0.8-2.6\]                0.226                        
  Saturday                                      8.61(13)                91.39(138)          0.7\[0.4-1.5\]                0.408                        
  Sunday                                        11.35(21)               88.65(164)          0.8\[0.5-1.3\]                0.365                        

^1.^ Denominators used to calculate proportions were adjusted for the number of patients in whom data were available. *OR* odds ratio, *CI* confidence interval.

Discussion
==========

Screening patients for MRSA carriage on admission to hospital is an increasingly important component of hospital MRSA control programs. Many programs rely on prediction tools so that patients at high risk of MRSA carriage may be targeted for selective screening rather than to utilise universal screening which is costly and resource intensive. Ideally, prediction tools are formulated using local epidemiological data from (universal) surveillance studies. However, many of these studies report a substantial rate of patients who are eligible for screening, but fail to be enrolled by the surveillance programme. The characteristics of these patients are seldom described.

In this study, 13.6% of patients failed to have admission MRSA screening swabs performed. This rate of "missed" screening opportunities is comparable to that found in other MRSA risk profiling studies \[[@B8]-[@B11],[@B14]\]. Patients who were not screened differed from those who were in several ways. Firstly, younger patients (\<50 years) were more likely to be missed during MRSA screening. A possible explanation for this is that nurses perceived younger patients to be at low risk for MRSA carriage and were thus less inclined to pursue screening. Although older age is frequently identified as a risk factor for MRSA carriage \[[@B8],[@B10],[@B12]\], it is possible that the tendency to miss younger patients from screening may contribute to this finding and inflate effect estimates. Transfer to internal medicine from another hospital department (intra-hospital transfer) was also a risk factor for being missed during screening. Intra-hospital transfer has been previously identified as a risk factor for MRSA admission carriage \[[@B10]\]; missing this group of patients could result in an underestimation of the true MRSA carriage rate and a failure to recognise intra-hospital transfer as an important risk factor for MRSA carriage. Patients with malignancy were more likely to be missed during screening in our study. This was due to logistic difficulties (e.g. frequent readmissions for chemotherapy; ultra-short hospitalizations) within our hospital oncology ward that impeded their regular participation in screening, and was therefore a problem specific to our institution.

To our knowledge, the study by Furano et al. is the only one to report detailed characteristics of patients missed by MRSA screening \[[@B11]\]. In this study, 83.7% of eligible patients were not enrolled in screening. Un-enrolled patients were older, less likely to have had a hospital admission in the previous year, and had a higher in-hospital mortality than those patients who were enrolled \[[@B11]\]. The present study will help to further elucidate the importance and magnitude of misclassification bias in MRSA risk profiling studies.

Our study has several limitations. Firstly, it is likely that the effectiveness of hospital surveillance programmes to enrol patients on admission may be heavily influenced by institutional and local factors. Therefore, the generalizability of our findings may be limited. Secondly, some of our data was collected retrospectively from medical records and is therefore subject to the inaccuracies inherent to data collected in this way.

Nevertheless, we believe that our findings highlight some of the potential misclassification biases that may occur in MRSA risk profiling studies due to patients missed from screening. This could have important implications for the accuracy of MRSA risk scores developed to target MRSA screening. Clear reporting on patient recruitment and the proportions and characteristics of those patients missed is essential for accurate interpretation of clinical prediction tools identifying patients at high risk for carriage of antibiotic-resistant bacteria.
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